Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
Defunding Scientific Research: Implications and Misconceptions in GawandeR...
FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough i...
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition M...
Advancing Pediatric Leukemia Trial: Precision Medicine and Transformative Res...
Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron ...
Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from ...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...